Literature DB >> 8809797

Gabaergic transmission and tyrosine hydroxylase expression in the nigral dopaminergic neurons: an in vivo study using a reversible ischemia model of rats.

K Yamada1, S Goto, M Yoshikawa, Y Ushio.   

Abstract

The authors conducted an in vivo study, using a rat striatal ischemic model, of the effect of GABAergic transmission upon the dopamine synthesizing enzyme tyrosine hydroxylase in the neurons of the substantia nigra pars compacta. Two hours transient middle cerebral artery occlusion produced massive striatal ischemic damage resulting in a marked decrease of GABAergic projection to the ipsilateral substantia nigra. Histological examinations were conducted in rats killed at three, seven, 15, 30 and 94 days after ischemia. The immunoreactivity for tyrosine hydroxylase in the ipsilateral pars compacta was unaltered up to three days after the ischemic insult, but it was markedly decreased at seven days post-ischemia. At this stage, the number of neurons positive for tyrosine hydroxylase was significantly decreased in the ipsilateral pars compacta, whereas there was no significant reduction in the number of pars compacta neurons containing Nissl substance. By 30 days post-ischemia, the tyrosine hydroxylase-positive cell number in the ipsilateral pars compacta appeared to be equivalent to that of the contralateral side. It was also noted that continuous intraventricular administration of a GABAA receptor agonist muscimol, initiated from 24 h post-ischemia, effectively prevented the transient reduction of immunoreactivity for tyrosine hydroxylase in the ipsilateral pars compacta at seven and 15 days after ischemic insult. The present study revealed that the striatal ischemic lesion induced a transient down-regulation of tyrosine hydroxylase synthesis in the pars compacta neurons, which could be prevented by administration of GABA agonist, suggesting that GABAergic transmission greatly affects dopamine metabolism in these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8809797     DOI: 10.1016/0306-4522(96)00041-3

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  7 in total

1.  Incremental conductance levels of GABAA receptors in dopaminergic neurones of the rat substantia nigra pars compacta.

Authors:  A Guyon; S Laurent; D Paupardin-Tritsch; J Rossier; D Eugène
Journal:  J Physiol       Date:  1999-05-01       Impact factor: 5.182

2.  A role of netrin-1 in the formation of the subcortical structure striatum: repulsive action on the migration of late-born striatal neurons.

Authors:  T Hamasaki; S Goto; S Nishikawa; Y Ushio
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 3.  Neuronal Cell Death.

Authors:  Michael Fricker; Aviva M Tolkovsky; Vilmante Borutaite; Michael Coleman; Guy C Brown
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

4.  MRI heralds secondary nigral lesion after brain ischemia in mice: a secondary time window for neuroprotection.

Authors:  Vincent Prinz; Anna-Maria Hetzer; Susanne Müller; Mustafa Balkaya; Christoph Leithner; Golo Kronenberg; Matthias Endres
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-01       Impact factor: 6.200

5.  Forebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats.

Authors:  B Lin; S Levy; A P Raval; M A Perez-Pinzon; R A Defazio
Journal:  Cardiovasc Psychiatry Neurol       Date:  2010-10-14

6.  Neuroprotective Effects of Salidroside on Cerebral Ischemia/Reperfusion-Induced Behavioral Impairment Involves the Dopaminergic System.

Authors:  Zhi-Feng Zhong; Jing Han; Ji-Zhou Zhang; Qing Xiao; Jing-Yan Chen; Kai Zhang; Juan Hu; Li-Dian Chen
Journal:  Front Pharmacol       Date:  2019-12-13       Impact factor: 5.810

Review 7.  The Intersection of Central Dopamine System and Stroke: Potential Avenues Aiming at Enhancement of Motor Recovery.

Authors:  Annette Gower; Mario Tiberi
Journal:  Front Synaptic Neurosci       Date:  2018-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.